Business Description
Kronos Bio Inc
NAICS : 541714
SIC : 2833
1300 So. El Camino Real, Suite 300, San Mateo, CA, USA, 94402
Description
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.06 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.21 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 0 | |||||
Beneish M-Score | 0 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -127.9 | |||||
3-Year EPS without NRI Growth Rate | -104.7 | |||||
3-Year FCF Growth Rate | -103.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.11 | |||||
9-Day RSI | 47.61 | |||||
14-Day RSI | 50.8 | |||||
6-1 Month Momentum % | -41.1 | |||||
12-1 Month Momentum % | -77.83 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 18.19 | |||||
Quick Ratio | 18.19 | |||||
Cash Ratio | 17.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.1 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -41.77 | |||||
ROA % | -37.25 | |||||
ROIC % | -266.69 | |||||
ROC (Joel Greenblatt) % | -389.72 | |||||
ROCE % | -38.52 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.86 | |||||
Price-to-Tangible-Book | 0.92 | |||||
EV-to-EBIT | -0.11 | |||||
EV-to-Forward-EBIT | -0.41 | |||||
EV-to-EBITDA | -0.11 | |||||
EV-to-FCF | -0.36 | |||||
Price-to-Net-Current-Asset-Value | 1.19 | |||||
Price-to-Net-Cash | 1.23 | |||||
Earnings Yield (Greenblatt) % | -904.26 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:KRON
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0 | ||
EPS (TTM) ($) | -2.98 | ||
Beta | 0 | ||
Volatility % | 60.9 | ||
14-Day RSI | 50.8 | ||
14-Day ATR ($) | 0.403698 | ||
20-Day SMA ($) | 4.95275 | ||
12-1 Month Momentum % | -77.83 | ||
52-Week Range ($) | 2.96 - 25.01 | ||
Shares Outstanding (Mil) | 56.77 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Kronos Bio Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |